UBS Group
KYTX icon

UBS Group’s Kyverna Therapeutics KYTX Stock Holding History

UBS Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.88M Buy
449,750
+247,563
+122% +$2.06M ﹤0.01% 4333
2025
Q4 		$1.9M Buy
202,187
+44,765
+28% +$332K ﹤0.01% 5027
2025
Q3 		$945K Buy
157,422
+59,264
+60% +$237K ﹤0.01% 5624
2025
Q2 		$301K Sell
98,158
-79,512
-45% -$197K ﹤0.01% 6437
2025
Q1 		$343K Sell
177,670
-25,733
-13% -$76K ﹤0.01% 6141
2024
Q4 		$761K Buy
203,403
+195,207
+2,382% +$935K ﹤0.01% 5531
2024
Q3 		$40.1K Sell
8,196
-1,448
-15% -$11.2K ﹤0.01% 6958
2024
Q2 		$72.3K Sell
9,644
-15,254
-61% -$233K ﹤0.01% 6401
2024
Q1 		$618K Buy
+24,898
New +$695K ﹤0.01% 5025

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

UBS Group's KYTX Position: Q1 2026 in Review

UBS Group increased its Kyverna Therapeutics (KYTX) stake by 122% in Q1 2026, buying an estimated $2.06M and bringing the position to 449,750 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #4333.

UBS Group first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • UBS Group held 449,750 shares of Kyverna Therapeutics worth $3.88M as of Q1 2026.
  • UBS Group bought 247,563 Kyverna Therapeutics shares in Q1 2026, an estimated $2.06M.
  • Kyverna Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4333 holding.
  • UBS Group first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.